Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Adapalene-Benzoy Peroxide (BPO) Gel in the Treatment of Acne Vulgaris as a 6-month Maintenance

ClinicalTrials.gov ID: NCT00687908

Public ClinicalTrials.gov record NCT00687908. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 4, 2026, 4:21 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Efficacy and Safety Comparison of Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel Versus Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel Vehicle Gel as a 6-month Acne Maintenance Treatment

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to demonstrate the efficacy of Adapalene 0.1% /Benzoyl Peroxide 2.5% Gel compared to its Vehicle Gel as an acne maintenance treatment in Subjects previously treated with Adapalene-BPO Gel or Adapalene-BPO Vehicle Gel both associated with Doxycycline Hyclate 100 mg. The safety of the two investigational treatments will also be assessed.

Study identification

NCT ID
NCT00687908
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Galderma R&D
Industry
Enrollment
243 participants

Conditions and interventions

Eligibility (public fields only)

Age range
12 Years to 35 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Oct 31, 2008
Primary completion
Jun 30, 2009
Completion
Jun 30, 2009
Last update posted
Feb 17, 2021

2008 – 2009

United States locations

U.S. sites
27
U.S. states
18
U.S. cities
27
Facility City State ZIP Site status
Galderma Investigational Site San Diego California
Galderma Investigational Site Denver Colorado
Galderma Investigational Site Longmont Colorado
Galderma Investigational Site Miami Florida
Galderma Investigational Site Snellville Georgia
Galderma Investigational Site Chicago Illinois
Galderma Investigational Site Evansville Indiana
Galderma Investigational Site Overland Park Kansas
Galderma Investigational Site Louisville Kentucky
Galderma Investigational Site Detroit Michigan
Galderma Investigational Site Fort Gratiot Michigan
Galderma Investigational Site Fridley Minnesota
Galderma Investigational Site Omaha Nebraska
Galderma Investigational Site Albuquerque New Mexico
Galderma Investigational Site Stony Brook New York
Galderma Investigational Site Winston-Salem North Carolina
Galderma Investigational Site Warren Ohio
Galderma Investigational Site Hazleton Pennsylvania
Galderma Investigational Site Hershey Pennsylvania
Galderma Investigational Site Simpsonville South Carolina
Galderma Investigational Site Arlington Texas
Galderma Investigational Site Austin Texas
Galderma Investigational Site College Station Texas
Galderma Investigational Site Houston Texas
Galderma Investigational Site Lubbock Texas
Galderma Investigational Site San Antonio Texas
Galderma Investigational Site Webster Texas 77598

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 6 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00687908, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Feb 17, 2021 · Synced Sep 4, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00687908 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →